In utero SSRI exposure tied to risk for mental disorders in offspring

  • Halvorsen A & al.
  • Acta Psychiatr Scand
  • 2 Apr 2019

  • curated by Pavankumar Kamat
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

A recent meta-analysis suggests that in utero exposure to selective serotonin reuptake inhibitors (SSRIs) may be associated with an increased risk for mental and/or behavioural disorders in the offspring, without evidence of a causal relationship.

Researchers conducted a meta-analysis of 18 studies identified through a literature search on the PubMed, Embase and PsycINFO databases.

The findings showed a statistically significant association between in utero exposure to SSRIs and mental and/or behavioural disorders including autism spectrum disorder (HR, 1.27; 95% CI, 1.10-1.47), attention-deficit/hyperactivity disorder (HR, 1.33; 95% CI, 1.06-1.66) and mental retardation (HR, 1.41; 95% CI, 1.03-1.91). Of the 7 studies that showed a positive association between exposure to any SSRI during any trimester of pregnancy and the development of a mental disorder, 5 studies found confounding by indication.

However, the authors warn that the risk of residual confounding in the meta-analysis remains substantial owing to inconsistent adjustment for potential confounders across the included studies. The is no evidence supporting a causal relationship between exposure to SSRIs in utero and mental and/or behavioural disorders in offspring.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit